Structure Therapeutics (NASDAQ:GPCR) Hits New 12-Month Low – Should You Sell?

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $25.74 and last traded at $25.80, with a volume of 324671 shares. The stock had previously closed at $27.04.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $50.00 target price for the company. Morgan Stanley initiated coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 23rd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Price Performance

The firm’s 50 day moving average is $32.35 and its 200 day moving average is $36.63. The company has a market capitalization of $1.46 billion, a PE ratio of -34.45 and a beta of -2.78.

Institutional Investors Weigh In On Structure Therapeutics

A number of large investors have recently modified their holdings of the stock. Point72 Asset Management L.P. lifted its stake in shares of Structure Therapeutics by 196.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock valued at $54,348,000 after purchasing an additional 820,589 shares during the period. Janus Henderson Group PLC lifted its position in Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after buying an additional 602,609 shares during the period. Vestal Point Capital LP boosted its holdings in shares of Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after buying an additional 590,000 shares in the last quarter. First Light Asset Management LLC grew its position in shares of Structure Therapeutics by 296.1% in the 2nd quarter. First Light Asset Management LLC now owns 590,647 shares of the company’s stock worth $23,195,000 after buying an additional 441,534 shares during the period. Finally, FMR LLC grew its position in shares of Structure Therapeutics by 6.7% in the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after buying an additional 383,635 shares during the period. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.